News
INFI
--
0.00%
--
Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Zacks.com · 1d ago
Infinity Pharmaceuticals Hosting Webinar On MARIO-3 And MARIO-275 Phase 2 Trials
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a
Benzinga · 4d ago
Infinity Pharma wins buy rating from B. Riley ahead of key milestone
Marcelo Ricardo Daros/iStock via Getty Images B. Riley Securities has initiated the coverage of Infinity Pharmaceuticals ([[INFI]] -2.6%) with a buy rating highlighting the potential of the company’s immune-oncology candidate
Seekingalpha · 07/07 15:18
Infinity to Present at The Keystone Symposia Precision Oncology Meeting
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune...
Business Wire · 06/14 12:35
Shareholders May Be More Conservative With Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation For Now
Performance at Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ) has been reasonably good and CEO Adelene Perkins has done...
Simply Wall St. · 06/03 08:39
We're Not Very Worried About Infinity Pharmaceuticals' (NASDAQ:INFI) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. By way of example, Infinity...
Simply Wall St. · 05/28 08:17
Infinity Pharmaceuticals Files for $250 Million Mixed-Securities Shelf Offering
MT Newswires · 05/14 05:33
Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates
Infinity (INFI) delivered earnings and revenue surprises of -7.14% and 0.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/13 22:35
BRIEF-Infinity Pharmaceuticals Reports Q1 2021 Financial Results And Provides Company Update
reuters.com · 05/13 21:34
BRIEF-Infinity Pharmaceuticals Inc Files For Mixed Shelf Of Up To $250 Million – SEC Filing
reuters.com · 05/13 21:19
Infinity Pharmaceuticals: Q1 Earnings Insights
Shares of Infinity Pharmaceuticals (NASDAQ:INFI) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 21.05% year over year to ($0.15), which missed the estimate of ($0.12).
Benzinga · 05/13 20:40
Infinity Pharmaceuticals Q1 EPS $(0.15) Misses $(0.12) Estimate
Infinity Pharmaceuticals (NASDAQ:INFI) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.12) by 25 percent. This is a 21.05 percent increase over losses of $(0.19) per
Benzinga · 05/13 20:27
Infinity Pharmaceuticals EPS misses by $0.01, beats on revenue
Infinity Pharmaceuticals (INFI): Q1 GAAP EPS of -$0.15 misses by $0.01.Revenue of $0.47M (+9.3% Y/Y) beats by $0.12M.Press Release
Seekingalpha · 05/13 20:14
Infinity Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Company Update
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced i...
Business Wire · 05/13 20:05
Infinity Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time.
ACCESSWIRE · 05/13 18:30
-- Earnings Flash (INFI) INFINITY PHARMACEUTICALS Posts Q1 Loss $-0.15
MT Newswires · 05/13 16:33
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 05/13 12:10
Earnings Scheduled For May 13, 2021
  Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
Benzinga · 05/13 08:15
Infinity Announces the Date of Its First Quarter 2021 Financial Results Conference Call and Webcast
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that addresses a fundamental biologic mechanism of immune ...
Business Wire · 05/06 11:35
Infinity to Present at New York Academy of Sciences Frontiers in Cancer Immunotherapy 2021
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that addresses a fundamental biologic mechanism of immune ...
Business Wire · 05/05 13:35
Webull provides a variety of real-time INFI stock news. You can receive the latest news about Infinity Pharma through multiple platforms. This information may help you make smarter investment decisions.
About INFI
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.